靶向 CD19、CD20 和 CD22 的床旁制备三特异性 CAR-T 细胞首次人体试验的安全性与临床结局

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

携带 BLM 突变的 DLBCL 患者在接受 CD19/CD22 双特异性 CAR-T 细胞治疗后发生继发性外周 T 细胞淋巴瘤

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

复发/难治性大 B 细胞淋巴瘤中基线免疫细胞组成与 CAR-T 细胞扩增及生存的关联

Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma.

基线免疫细胞组成可能与 R/R 大 B 细胞淋巴瘤中 CAR-T 的扩增和结局相关。

DLBCL 活体供者接受 CD19/CD22 CAR-T 细胞鸡尾酒疗法后长期完全缓解及轻微副作用：一例罕见病例报告

Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.

ASCT 后序贯 CD19/CD22 CAR-T 细胞治疗在复发/难治性大 B 细胞淋巴瘤中较单纯 CAR-T 显示出更优疗效

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma.

双特异性抗体治疗失败后复发/难治性弥漫大 B 细胞淋巴瘤 CAR-T 细胞挽救治疗的疗效与安全性分析

Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody t

CAR-T 挽救治疗在 BsAb R/R DLBCL 患者中显示出高缓解率和可控的安全性。早期生存数据表明，在这一 BsAb 耐药的高危人群中具有令人鼓舞的临床获益，尽管需要延长随访以确认持久性。本研究为 CAR-T 作为该情境下的一种潜在挽救策略提供了支持性证据。

CD22 特异性 T 细胞受体实现 B 细胞恶性肿瘤的有效过继 T 细胞治疗

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.

2026 年白血病的照护与治愈

The Care and Cure of the Leukemias in 2026.

在靶点选择指导下，inotuzumab ozogamicin 成功挽救一例抗 CD19 和抗 CD22 CAR-T 细胞治疗后的难治性滤泡性淋巴瘤患者：病例报告与文献综述

Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CA

复发/难治性弥漫大 B 细胞淋巴瘤中单用 CD19/22 CAR-T 细胞或联合自体造血干细胞移植的长期治疗结局

Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL.